HR negative

Whole-genome sequencing of tumor samples carrying these germline risk variants revealed that they harbored mutational signatures indicative of a deficiency of homologous recombination. These findings suggest that hereditary POLH p.K589T and RAD51 p.M1fs are candidate variants associated with an increased risk of hormone receptor-negative breast cancer.

With adequate follow-up, distant disease-free survival is a robust surrogate endpoint for predicting final overall survival outcomes in neoadjuvant RCTs for early breast cancer in most contexts. However, the distant disease-free survival surrogacy appears to be weak for the hormone receptor-positive and HER2-negative and for the hormone receptor-positive and HER2-positive molecular subtypes. These latter findings warrant further investigation in more recent RCTs enrolling higher-risk patient populations.

Exploratory subgroup analysis further elucidated that OW/OB patients, particularly those aged > 50 years, postmenopausal, with lymph node involvement, hormone receptor negativity, or HER2 3 + status, exhibited substantially compromised pCR rates. Collectively, these findings substantiate the potential of BMI as a robust predictive biomarker for neoadjuvant therapy response in Chinese HER2-positive breast cancer patients.

Except for the worst OS in the constant HER2-zero, hormone receptor-negative subgroup, no significant differences were observed in the DFS and OS with respect to the changes of HER2-zero and HER2-low groups. The prognostic significance of HER2-zero and HER2-low changes after NAC requires further exploration through prospective studies.

The PTCH regimen demonstrated efficacy and a tolerable safety profile in patients with HER2+ BC in an Indian real-world setting. Achieving pCR is a significant predictor of improved DFS. The PTCH regimen obviates the need for adjuvant trastuzumab emtansine after surgery, making it a cost-effective strategy in a limited-resource setting.

P=N/A, N=60, Not yet recruiting, The First Affiliated Hospital of Xi 'an Jiaotong University; The First Affiliated Hospital of Xi 'an Jiaotong University

P2, N=38, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

P2, N=125, Not yet recruiting, Shengjing Hospital of China Medical University; Shengjing Hospital of China Medical University

P3, N=1056, Active, not recruiting, Alliance for Clinical Trials in Oncology | Recruiting --> Active, not recruiting

Clinicians and nurses should actively monitor patients for factors associated with CIPN during chemotherapy. Although interventions to improve QoL and enhance social support have been linked to lower CIPN severity, their causal impact on CIPN occurrence is not established and requires evaluation in future longitudinal studies.

This multicenter real-world study demonstrates that conventional inflammatory markers have limited predictive value, whereas the PNI emerges as a simple and practical biomarker reflecting nutritional and immune status. Integrating PNI with clinicopathological factors may enhance risk stratification and help guide individualized neoadjuvant treatment strategies in HER2-positive breast cancer.

Results confirm T-DXd as standard of care after prior chemotherapy in patients with HER2-low metastatic breast cancer. ClinicalTrials.gov identifier: NCT03734029 .